INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16201, 18352, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16202, 18425, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16203, 20272, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16204, 20929, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16205, 20930, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16206, 20931, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16207, 24859, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16208, 24872, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16209, 24875, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16210, 24876, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16211, 24877, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16212, 24878, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16213, 24879, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16214, 24880, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16215, 24881, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16216, 24882, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16217, 33404, 'Phenytoin', 'Hyperglycemia', 'Phenytoin, particularly in high dosages, may cause hyperglycemia by inhibiting insulin release.  The drug may also raise serum glucose levels in diabetic patients.  Therapy with phenytoin should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Patients with diabetes mellitus should be monitored more closely during phenytoin therapy, and their antidiabetic regimen adjusted accordingly.  The same precautions should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16218, 2177, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16219, 5954, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16220, 18352, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16221, 18425, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16222, 20272, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16223, 20929, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16224, 20930, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16225, 20931, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16226, 24859, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16227, 24872, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16228, 24875, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16229, 24876, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16230, 24877, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16231, 24878, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16232, 24879, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16233, 24880, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16234, 24881, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16235, 24882, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16236, 33404, 'Phenytoin', 'Anemia, Megaloblastic', 'Hydantoin anticonvulsants may interfere with folate metabolism and precipitate macrocytosis and megaloblastic anemia, which usually respond to folic acid therapy.  These reactions have been fairly uncommon but may be of concern in patients with megaloblastic anemia or folate deficiency receiving hydantoin therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16237, 2177, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16238, 5954, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16239, 18352, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16240, 18425, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16241, 20272, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16242, 20929, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16243, 20930, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16244, 20931, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16245, 24859, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16246, 24872, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16247, 24875, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16248, 24876, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16249, 24877, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16250, 24878, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16251, 24879, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16252, 24880, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16253, 24881, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16254, 24882, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16255, 33404, 'Phenytoin', 'Osteomalacia', 'Phenytoin may interfere with vitamin D metabolism.  Hypocalcemia and osteomalacia have been reported.  Therapy with phenytoin should be administered cautiously in patients with preexisting vitamin D deficiency.  The same precaution should also be observed with other hydantoin anticonvulsants (i.e. ethotoin and mephenytoin) because of their structural and pharmacological similarities to phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16256, 2177, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16257, 5954, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16258, 18352, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16259, 18425, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16260, 20272, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16261, 20929, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16262, 20930, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16263, 20931, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16264, 24859, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16265, 24872, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16266, 24875, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16267, 24876, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16268, 24877, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16269, 24878, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16270, 24879, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16271, 24880, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16272, 24881, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16273, 24882, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16274, 33404, 'Phenytoin', 'Alcoholism', 'The use of acute alcoholic intake may increase phenytoin serum levels while chronic alcoholic use may decrease serum levels.  Caution is recommended in alcoholic patients.  The same precaution should also be observed with fosphenytoin as this agent is a prodrug of phenytoin.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16275, 2177, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16276, 5954, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16277, 18352, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16278, 18425, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16279, 20272, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16280, 20929, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16281, 20930, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16282, 20931, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16283, 24859, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16284, 24872, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16285, 24875, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16286, 24876, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16287, 24877, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16288, 24878, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16289, 24879, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16290, 24880, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16291, 24881, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16292, 24882, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16293, 33404, 'Phenytoin', 'Thyroid Diseases', 'Phenytoin may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Free thyroxine concentrations may also be decreased, while resin or red cell T3 uptake values may be increased.  Clinicians should be cognizant of these effects when prescribing or administering phenytoin therapy to patients with thyroid disorders.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16294, 0, 'Pimavanserin', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16295, 0, 'Pimavanserin', 'Neuroleptic Malignant Syndrome', 'The central dopaminergic blocking effects of neuroleptic agents may precipitate or aggravate a potentially fatal symptom complex known as neuroleptic malignant syndrome (NMS).  NMS is observed most frequently when high-potency agents like haloperidol are administered intramuscularly, but may occur with any neuroleptic agent given for any length of time.  Clinical manifestations of NMS include hyperpyrexia, muscle rigidity, altered mental status and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis and cardiac arrhythmias).  Additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure.  Neuroleptic agents should not be given to patients with active NMS and should be immediately discontinued if currently being administered in such patients.  In patients with a history of NMS, introduction or reintroduction of neuroleptic agents should be carefully considered, since NMS may recur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16296, 0, 'Pimavanserin', 'Hepatic Insufficiency', 'The use of pimavanserin is not recommended in patients with hepatic impairment, as this drug has not been evaluated in this patient population.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16297, 0, 'Pimavanserin', 'Long QT Syndrome', 'Pimavanserin prolongs the QT interval and should be avoided in patients with known QT prolongation or in patients taking other drugs known to prolong QT interval (class 1A and class 3 antiarrhythmics, certain antipsychotics, and some antibiotics).  Pimavanserin should also be avoided in patients with cardiac arrhythmias and other circumstances that might increase the risk of the occurrence of Torsade de Pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16298, 0, 'Pimavanserin', 'Seizures', 'Antipsychotic and neuroleptic drugs can lower the seizure threshold and trigger seizures in a dose-dependent manner.  This risk is greatest in patients with a history of seizures or with conditions that lower the seizure threshold.  Therapy with these drugs should be administered cautiously in patients with a history of seizures or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16299, 0, 'Pimavanserin', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, and agranulocytosis have been reported with the use of atypical antipsychotic agents.  Patients with preexisting low white blood cell count may be at increased risk.  Therapy with these agents should be administered cautiously in patients with a history of, or predisposition to, decreased white blood cell or neutrophil counts.  Clinical monitoring of hematopoietic function is recommended.  At the first sign of a clinically significant decline in white blood cells, discontinuation of atypical antipsychotic therapy should be considered in the absence of other causative factors, and the patient closely monitored for fever or other signs and symptoms of infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16300, 0, 'Pimavanserin', 'Hyperglycemia', 'Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported with the use of atypical antipsychotic agents.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents.  It is recommended that patients with risk factors for diabetes mellitus starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment, and periodically thereafter.  Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.  Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.  In some cases, hyperglycemia has resolved when treatment with these agents was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the atypical antipsychotic drug.', '2', '', 'DDInter', 0);
